Skip to content

Aloe Vera and Chlorhexidine Against Traumatic Oral Ulcers

Aloe Vera and Chlorhexidine as Preventive Oral Antiseptics Against the Appearance of Traumatic Oral Ulcers in Patients With Fixed Orthodontics: a Randomized Clinical Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03633292
Enrollment
140
Registered
2018-08-16
Start date
2015-01-31
Completion date
2018-01-31
Last updated
2018-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Ulcer

Brief summary

The development of gingivitis in patients during orthodontic treatment is widely known, with the characteristic response of gingival inflammation and hyperplasia and traumatic rashes or ulcerations of the oral mucosa derived from the treatment. The use of chemical agents such as CHX, although it has proven to be useful in these patients, but has the disadvantage of having side effects such as staining, even restricting its use during treatment. The objective of this study was to determine the efficacy of Aloe vera gel at 80% compared to 0.12% Chlorhexidine gel to alleviate the effects derived from any orthodontic treatment, such as gingival inflammation and hyperplasia and friction or ulcerations. of traumatic oral mucosa-derived from treatment in patients after cementation with metal brackets in the two arches. A total of 140 patients between the ages of 10 and 55 who were randomized and assigned in the two study groups treated with Aloe vera gel versus the conventional Chlorhexidine gel with a sample of 70 subjects in each group participated. The index of gingival inflammation, plaque index, as well as the simplified hemorrhage index, were evaluated.

Interventions

DRUGAntiseptic clorhexidine gel (Lacer, Barcelona, Spain)

Together with the dispensing container, the dosing and dosage of the gel in research will be attached, with the description of the pharmaceutical form, packaging and labeling of the product. Packages with 8 ml of the gel under investigation, sufficient treatment for 1 month of applications. Posology: After tooth brushing, apply a small amount of gel on the fingertip of a freshly washed finger and spread it over the gum, doing a gentle massage, for 15 , 2 times a day after proper oral hygiene and it is recommended not to ingest no liquid or food until after half an hour of use.

DRUGMaster formula of aloe vera gel 80%

Blindly and in the same container as chlorhexidine, patients will be instructed to apply aloe vera gel on the gums and mucous membranes once the orthodontic appliances have been cemented

Sponsors

Alfonso X El Sabio University
CollaboratorOTHER
University of Santiago de Compostela
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
11 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients who have just begun orthodontic treatment after bracket cementation. * Be willing and have signed the informed consent. * Presence of cemented metal brackets throughout the upper and lower arches. * Presence of good oral health: dental, periodontal and soft tissue

Exclusion criteria

* Allergic or who have suffered adverse reactions to Chlorhexidine or Aloe Vera. * Pregnant, since they are not claimants of fixed multibrackets appliances. * Presence of auxiliary extraoral appliances during the treatment that may cause additional injuries. * Under 11 years old.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of traumatic oral ulcers30 daysThe patient will attend his scheduled appointment for bracket cementation. Before cementing, we will complete the clinical history (frequency of brushing, smoker or non-smoker, age, sex) aided by intraoral photographs, always collected in the same order according to protocol and by the same researcher. After the cementation, the patient will be included in the study in a random way in the corresponding group. One month after cementing and coinciding with the periodic visit of the patient, the presence / absence of friction or traumatic ulcers will be evaluated.

Secondary

MeasureTime frameDescription
Prevalence of gingival inflammation30 daysOne month after cementing and coinciding with the periodic visit of the patient, the presence / absence gingival inflammation through the gingival inflammation index will be evaluated. 0 = Normal gingiva, absence of inflammation, no change in color, no bleeding. 1 = slight inflammation, slight change in color, small alteration of the surface, no hemorrhage. 2 = Moderate inflammation, redness, edema and hemorrhage on probing and pressure. 3 = Strong inflammation, intense redness, edema, tendency to hemorrhages, eventually ulceration. It is interpreted as follows: Sum of the degree of each face / No. of faces observed 0.0-1.0 = incipient gingivitis 1.1-2.0 = Moderate gingivitis 2,1-3,0 = Severe gingivitis
Prevalence of gingival bleeding30 daysOne month after cementing and coinciding with the periodic visit of the patient, the presence / absence of gingival bleeding through the gingival index or Simplified haemorrhage index (DHI). It is taken on four sides of the tooth, distal, vestibular, mesial and palatal. The average of the four measurements will be the value of that patient. Periodontal probe will be used. 0 = absence of hemorrhage; 1 = presence of haemorrhage.

Other

MeasureTime frameDescription
Security and tolerability - number of participants with treatment related adverse events as assessed by CTCAE v4.030 daysThe study subject is obliged to communicate, by telephone or personally, any type of symptom: redness (erythema), thickening (edema) and peeling (ulcer) occurred after application of the products under study, and will must immediately interrupt the use of it, registering the adverse effects and number of participants with treatment related adverse events as assessed by CTCAE v4.0 and using as a rescue product for the treatment of contact mucositis and antiallergic drugs.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026